Asset

Hypericin

Soligenix Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (1)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT02448381phase3completed2015-12-012020-06-01SoligenixFLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)